ArticleMolecular medicine (Cambridge, Mass.)2022
NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals.
Open access · goldAbstract read
In one paragraph
Article in Molecular medicine (Cambridge, Mass.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 42 citations in OpenAlex.
- Effects of natural killer cell depletion on innate and adaptive immune responses to COVID mRNA vaccination.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- Natural killer cells against viral infection: from basic biology to immunotherapy.Precision clinical medicine · 2026Review
- Possible role of pre-vaccination T-lymphocyte subpopulations in the antibody response to COVID-19 vaccines in children undergoing chemotherapy.Frontiers in immunology · 2026Article
- Mapping NK cell diversity in response to COVID-19 and mRNA vaccination.Scientific reports · 2025Article
- Systems vaccinology identifies immunological correlates of SARS-CoV-2 vaccine response in solid organ transplant recipients.NPJ vaccines · 2025Article
- Spectral Flow Cytometry: The Current State and Future of the Technology.International journal of molecular sciences · 2025Review
- Murine modeling of menstruation identifies immune correlates of protection during Chlamydia muridarum challenge.PLoS pathogens · 2025Article
- Functional T cell response to COVID-19 vaccination with or without natural infection with SARS-CoV-2 in adults and children.Scientific reports · 2025Article
- Article
- Single-Cell RNA Sequencing of Baseline Immune Profiles After Third Vaccination Associated with Subsequent SARS-CoV-2 Infection in Naïve Individuals.International journal of molecular sciences · 2025Article
- From natural defenders to therapeutic warriors: NK cells in HIV immunotherapy.Immunotherapy · 2025Review
- Poxvirus Vectors Activate Human NK and MAIT Cells in a Type I Interferon, IL-18, and Monocyte-Dependent Manner.Journal of immunology research · 2025Article
- Beyond interferon gamma - decreased cellular response to COVID-19 vaccination booster in patients with autoimmune inflammatory rheumatic diseases.Frontiers in immunology · 2025Article
- An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity.Vaccines · 2024Review
- Premature skewing of T cell receptor clonality and delayed memory expansion in HIV-exposed infants.Nature communications · 2024Article
- Interaction dynamics between innate and adaptive immune cells responding to SARS-CoV-2 vaccination in non-human primates.Nature communications · 2023Article
- Natural killer cell responses during SARS-CoV-2 infection and vaccination in people living with HIV-1.Scientific reports · 2023Article
- Article
- Waning cellular immune responses and predictive factors in maintaining cellular immunity against SARS-CoV-2 six months after BNT162b2 mRNA vaccination.Scientific reports · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 2 institutions in 1 country.
Angelica CuapioDepartment of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Caroline Boulouis *Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Iva Filipovic *Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
David Wullimann *Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Tobias KammannDepartment of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Tiphaine ParrotDepartment of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Puran ChenDepartment of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Mira AkberDepartment of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Yu GaoDepartment of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Quirin HammerDepartment of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Benedikt StrunzDepartment of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
André Pérez PottiDepartment of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Olga Rivera BallesterosDepartment of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Joshua LangeDepartment of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Jagadeeswara Rao MuvvaDepartment of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Peter BergmanDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Ola BlennowDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Lotta HanssonDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Stephan MielkeDepartment of Laboratory Medicine, Biomolecular and Cellular Medicine, Karolinska Institutet, Stockholm, Sweden.
Piotr NowakDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Gunnar SöderdahlDepartment of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Anders ÖsterborgDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
C I Edvard SmithDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Gordana BogdanovicDepartment of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.
Sandra MuschiolDepartment of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.
Fredrika HellgrenDepartment of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Karin LoréDepartment of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Michal J SobkowiakDepartment of Dental Medicine, Karolinska Institutet, Stockholm, Sweden.
Giorgio GabarriniDepartment of Dental Medicine, Karolinska Institutet, Stockholm, Sweden.
Katie HealyDepartment of Dental Medicine, Karolinska Institutet, Stockholm, Sweden.
Margaret Sällberg ChenDepartment of Dental Medicine, Karolinska Institutet, Stockholm, Sweden.
Evren AliciDepartment of Medicine Huddinge, Hematology and Regenerative Medicine, Karolinska Institutet, Stockholm, Sweden.
Niklas K BjörkströmDepartment of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Marcus BuggertDepartment of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Per LjungmanDepartment of Hematology, Karolinska University Hospital, Stockholm, Sweden.
Johan K SandbergDepartment of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden.
Soo AlemanDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Hans-Gustaf LjunggrenDepartment of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, 141 52, Stockholm, Sweden. hans-gustaf.ljunggren@ki.se.ORCID 0000-0003-0908-7387
Karolinska University Hospital · SEKarolinska Institutet · SE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adaptive immune responses have been studied extensively in the course of mRNA vaccination against COVID-19. Considerably fewer studies have assessed the effects on innate immune cells. Here, we characterized NK cells in healthy individuals and immunocompromised patients in the course of an anti-SARS-CoV-2 BNT162b2 mRNA prospective, open-label clinical vaccine trial. See trial registration description in notes. Results revealed preserved NK cell numbers, frequencies, subsets, phenotypes, and function as assessed through consecutive peripheral blood samplings at 0, 10, 21, and 35 days following vaccination. A positive correlation was observed between the frequency of NKG2C
Indexed as
AdolescentAdultAntibodies, ViralBNT162 VaccineCOVID-19COVID-19 VaccinesFemaleFlow CytometryHumansImmunocompromised HostKiller Cells, NaturalLymphocyte CountMaleMiddle AgedNK Cell Lectin-Like Receptor Subfamily COutcome Assessment, Health CareAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesKLRC2 protein, humanNK Cell Lectin-Like Receptor Subfamily CAnti-SARS-CoV-2 antibodiesBNT162b2 mRNA vaccineClinical trialCOVID-19Innate immunitymRNA vaccineNK cellsNKG2CSARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.